

PATENT

Docket No. 229752000700

Client Reference 2178670/EJH/AF

DAK


#5

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on November 2, 2000.

Renell G. Feimster

Renell G. Feimster



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Paul Z. ZIMMET et al.

Serial No.: 09/331,930

Filing Date: June 30, 1999

For: A NOVEL GENE AND USES THEREFOR

Examiner: Garnette D. Draper

Group Art Unit: 1647

RECEIVED

NOV 06 2000

OFFICE OF PETITIONS

PETITION UNDER 37 CFR § 1.182

Commissioner for Patents
Washington, D.C. 20231

Attn: PCT Legal Office

Sir:

The applicants hereby request that the two attached sheets of drawing figures be included with the specification of this U.S. national stage application. The applicants believe that these drawing figures should be incorporated into the application as though filed with the original specification on June 30, 1999. A copy of International Application No. PCT/AU98/00902, from which this application claims priority, included these drawing figures and was received by the U.S. Patent and Trademark Office from the International Bureau by the time this application was filed. Since this application claims the priority of an international application that was included with this application at the time of filing, and the international application included both of the attached sheets of drawings, no new matter is being added.

11/03/2000 SUDONG 00000027 09331930

01 FC:122

130.00 OP


dc-234787

Attached is a check in the amount of \$130.00 to cover the petition fee set forth in 37 CFR § 1.17(h). In the event that the transmittal letter is separated from this document in the Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account Number 03-1952 referencing Docket Number 229752000700. However, the Commissioner is not authorized to charge the cost of the issue fee to the deposit account.

Respectfully submitted,

Dated: November 2, 2000

By:


Wayne C. Jaeschke, Jr.
Registration No. 38,503

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 778-1446
Facsimile: (202) 887-0763

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☒ 7. *See the above for sequence in the application*
Other:

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.